DDInter948 DDInter210
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delavirdine
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Binimetinib may lead to a major life threatening interaction when taken with Ramucirumab
Binimetinib may lead to a major life threatening interaction when taken with Zanubrutinib